The three Big Pharma companies on their earnings calls this week tried to reassure investors that they have the global footprints to mitigate the effects of tariffs.
The life sciences tools and services company said U.S.-China tariffs are expected to cut 2025 revenue by $400 million and adjusted operating income by $375 million.
Despite the widespread success of CAR T therapies, there have been challenging immunologic side effects such as cytokine release syndrome and neurotoxicity, which can now be mitigated...
The CDMO plans to build and expand small, medium, and large manufacturing facilities across Europe and the U.S. over the next three years to meet rising demand for peptides.
President Trump has threatened to impose tariffs on pharmaceuticals, as a Department of Commerce probe on drug imports gets underway. But analysts and stakeholders are skeptical...
While animal testing has been mandated for every drug since the 1930s, the drug development framework is changing — a long overdue and much needed change.
The agency has cited several drugmakers with warning letters, import alerts, and Form 483s for manufacturing lapses ranging from data integrity violations to sterility assurance...
Despite Trump pushing drugmakers to bring manufacturing back to the U.S., it remains unclear whether companies — other than Eli Lilly, J&J, and Novartis — will respond.
The CDMO, with 3,200 employees at 20 locations in the U.S., Europe and India, has a global footprint to help customers navigate their R&D and manufacturing challenges.
Despite Trump pushing drugmakers to bring manufacturing back to the U.S., it remains unclear whether companies — other than Eli Lilly, J&J, and Novartis — will respond.
The company says it is investing in areas across the value chain to ensure its customers continue to enjoy the benefits of a global network with local access.
With a digital-first foundation and deep IT/OT integration, many life sciences companies embrace cutting-edge cybersecurity solutions by leveraging innovation, collaboration and...
Despite Trump’s efforts to bring manufacturing back to the U.S., the threat of tariffs is accelerating an ongoing move to regional redundancy and capacity distribution.
The industry got a reprieve as pharmaceuticals were exempted from President Trump’s reciprocal tariffs announced this week. However, analysts expect it to be short-lived.
The White House on Wednesday said pharmaceuticals are exempted from the reciprocal tariffs. Jefferies analysts called the impact on biopharma “minimal” at least for now.
The Swiss-headquartered company has scaled up its operations to become a leading contract development and manufacturing organization focused on profitable growth.
This week, President Donald Trump doubled down on his threat to target the pharma industry with tariffs meant to bring drug manufacturing back to the United States.
With capabilities supporting its next-generation ADC pipeline scaled up externally, Sutro Biopharma’s operations in San Carlos, California will cease this year.
While the $925 million acquisition of Biovectra was completed in September, Agilent is bringing the Canadian CDMO up to its standards in terms of process and quality.
Major players in the contract development and manufacturing organization industry gathered in New York City this week to provide updates on their infrastructure investments.
The company is investing $1 billion in its Songdo Bio Campus in South Korea, with Plant 1 scheduled for completion this year and full-scale commercial production by 2027.
By automating and digitizing critical processes, Ori’s platform is designed to streamline manufacturing workflows and overcome bottlenecks that limit patient access.
Eli Lilly, Merck, Pfizer, Purdue University, and The Noramco Group are among the stakeholders looking to help address shortages in the U.S. injectable supply chain.
